/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed.
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate.
Artivion (NYSE:AORT – Free Report) had its price target lowered by Needham & Company LLC from $26.00 to $22.00 in a research report released on Friday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Artivion Stock Down 2.2 % Artivion stock opened at $13.91 on Friday. Artivion has a […]
Artivion (NYSE:AORT – Get Free Report) had its price target decreased by equities research analysts at Needham & Company LLC from $26.00 to $22.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective suggests a potential upside of 69.75% […]
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023.